Mn Services Vermogensbeheer B.V. reduced its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 7.3% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 456,455 shares of the biopharmaceutical company's stock after selling 35,700 shares during the quarter. Mn Services Vermogensbeheer B.V.'s holdings in Gilead Sciences were worth $51,146,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds also recently made changes to their positions in GILD. Bridgewater Associates LP increased its stake in Gilead Sciences by 122.7% during the fourth quarter. Bridgewater Associates LP now owns 460,936 shares of the biopharmaceutical company's stock worth $42,577,000 after acquiring an additional 253,994 shares during the last quarter. Nissay Asset Management Corp Japan ADV increased its holdings in Gilead Sciences by 5.2% during the 4th quarter. Nissay Asset Management Corp Japan ADV now owns 284,243 shares of the biopharmaceutical company's stock worth $26,750,000 after purchasing an additional 14,009 shares during the period. Ontario Teachers Pension Plan Board increased its stake in shares of Gilead Sciences by 54.6% during the fourth quarter. Ontario Teachers Pension Plan Board now owns 37,051 shares of the biopharmaceutical company's stock valued at $3,422,000 after buying an additional 13,086 shares during the period. Mufg Securities Americas Inc. purchased a new stake in shares of Gilead Sciences in the 4th quarter worth approximately $1,699,000. Finally, Convergence Investment Partners LLC lifted its holdings in Gilead Sciences by 15.8% during the fourth quarter. Convergence Investment Partners LLC now owns 68,447 shares of the biopharmaceutical company's stock worth $6,322,000 after buying an additional 9,330 shares during the period. 83.67% of the stock is currently owned by hedge funds and other institutional investors.
Insider Transactions at Gilead Sciences
In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the firm's stock in a transaction dated Thursday, May 22nd. The stock was sold at an average price of $107.52, for a total transaction of $3,010,560.00. Following the transaction, the insider now owns 121,152 shares of the company's stock, valued at approximately $13,026,263.04. This trade represents a 18.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction that occurred on Thursday, May 15th. The shares were sold at an average price of $99.82, for a total value of $249,550.00. Following the completion of the sale, the chief financial officer now directly owns 165,674 shares of the company's stock, valued at $16,537,578.68. The trade was a 1.49% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 43,000 shares of company stock valued at $4,630,310. 0.27% of the stock is currently owned by corporate insiders.
Analyst Upgrades and Downgrades
A number of analysts have recently weighed in on the stock. JPMorgan Chase & Co. raised their price target on shares of Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a report on Thursday, March 27th. Deutsche Bank Aktiengesellschaft upgraded Gilead Sciences from a "hold" rating to a "buy" rating and upped their target price for the company from $80.00 to $120.00 in a research report on Tuesday, February 18th. Needham & Company LLC restated a "hold" rating on shares of Gilead Sciences in a research note on Wednesday, May 21st. Morgan Stanley lifted their price objective on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a report on Friday, April 25th. Finally, Cantor Fitzgerald assumed coverage on Gilead Sciences in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 target price on the stock. Nine analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $110.55.
Read Our Latest Stock Analysis on GILD
Gilead Sciences Trading Down 1.8%
Shares of Gilead Sciences stock traded down $2.07 during mid-day trading on Friday, hitting $109.98. The stock had a trading volume of 8,148,740 shares, compared to its average volume of 7,744,306. Gilead Sciences, Inc. has a 12-month low of $62.69 and a 12-month high of $119.96. The firm has a market cap of $136.81 billion, a P/E ratio of 297.24, a price-to-earnings-growth ratio of 0.71 and a beta of 0.29. The firm has a 50-day moving average of $105.67 and a two-hundred day moving average of $102.26. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. The firm had revenue of $6.67 billion during the quarter, compared to analysts' expectations of $6.77 billion. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The firm's quarterly revenue was down .3% on a year-over-year basis. During the same quarter last year, the company posted ($1.32) EPS. Sell-side analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.
Gilead Sciences Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be issued a $0.79 dividend. The ex-dividend date is Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.87%. Gilead Sciences's payout ratio is 66.53%.
About Gilead Sciences
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Featured Stories
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
